Louisiana State University

LSU Digital Commons
Faculty Publications

School of Animal Sciences

1-1-1997

Transgenic Dairy Cattle: Genetic Engineering on a Large Scale
R. J. Wall
USDA ARS Beltsville Agricultural Research Center

D. E. Kerr
USDA ARS Beltsville Agricultural Research Center

K. R. Bondioli
USDA ARS Beltsville Agricultural Research Center

Follow this and additional works at: https://digitalcommons.lsu.edu/animalsciences_pubs

Recommended Citation
Wall, R., Kerr, D., & Bondioli, K. (1997). Transgenic Dairy Cattle: Genetic Engineering on a Large Scale.
Journal of Dairy Science, 80 (9), 2213-2224. https://doi.org/10.3168/jds.S0022-0302(97)76170-8

This Article is brought to you for free and open access by the School of Animal Sciences at LSU Digital Commons.
It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital Commons.
For more information, please contact ir@lsu.edu.

Transgenic Dairy Cattle:
Genetic Engineering on a Large Scale
R. J. WALL, D. E. KERR,1 and K. R. BONDIOLI2
Gene Evaluation and Mapping Laboratory, USDA-ARS-Livestock and
Poultry Science Institute, Beltsville, MD 20705

ABSTRACT
Amid the explosion of fundamental knowledge
generated from transgenic animal models, a small
group of scientists has been producing transgenic
livestock with goals of improving animal production
efficiency and generating new products. The ability to
modify mammary-specific genes provides an opportunity to pursue several distinctly different avenues of
research. The objective of the emerging gene “pharming” industry is to produce pharmaceuticals for treating human diseases. It is argued that mammary
glands are an ideal site for producing complex bioactive proteins that can be cost effectively harvested
and purified. Consequently, during the past decade,
approximately a dozen companies have been created
to capture the US market for pharmaceuticals
produced from transgenic bioreactors estimated at $3
billion annually. Several products produced in this
way are now in human clinical trials. Another
research direction, which has been widely discussed
but has received less attention in the laboratory, is
genetic engineering of the bovine mammary gland to
alter the composition of milk destined for human
consumption. Proposals include increasing or altering
endogenous proteins, decreasing fat, and altering
milk composition to resemble that of human milk.
Initial studies using transgenic mice to investigate
the feasibility of enhancing manufacturing properties
of milk have been encouraging. The potential profitability of gene “pharming” seems clear, as do the
benefits of transgenic cows producing milk that has
been optimized for food products. To take full advantage of enhanced milk, it may be desirable to restructure the method by which dairy producers are compensated. However, the cost of producing functional
transgenic cattle will remain a severe limitation to
realizing the potential of transgenic cattle until ineffi-
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ciencies of transgenic technology are overcome. These
inefficiencies include low rates of gene integration,
poor embryo survival, and unpredictable transgene
behavior.
( Key words: transgenic, bioreactor, genetic engineering, milk composition)
Abbreviation key: CoA = coenzyme A, hGH = human growth hormone.
INTRODUCTION
In 1987, Lothar Hennighausen and Heiner Westphal at the National Institutes of Health, in collaboration with Katy Gordon and her colleagues at Integrated Genetics, started a mini-revolution when
they reported that a pharmaceutical could be
produced in mammary glands of transgenic animals
(28). Within 5 yr of their report, a new industry was
formed, sponsored with venture capital. The remarkable speed with which transgenic animal bioreactor
technology moved from laboratories to industry attests to the perceived potential value of this approach
for producing pharmaceuticals. The dairy industry
has not embraced transgenic technology with the
same enthusiasm as the pharmaceutical industry. In
this review, we explain why and try to identify
productive areas of research that could provide supporting justification for the dairy industry to consider
the transgenic approach as a practical means to enhance the genetic potential of dairy cattle.
Goals for Genetic Engineering
of Mammary Glands
Commercial interests have fueled research on
modifying the genetic control of mammary glands for
the purpose of producing pharmaceutical proteins in
milk. However, this technology also offers the opportunity to alter the composition of bovine milk destined
for the dairy industry. A number of excellent reviews
(38, 49, 60, 82, 84) have been written on the topic.
The authors of those reviews have suggested strategies for changing milk composition to enhance cheese
yield, to reduce the energetic cost of milk production,
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TABLE 1. Milestones in transgenic animal bioreactor technology.
Year

Accomplishment

Reference

1980
1982
1987

Transgenic animal produced by pronuclear microinjection.
Fusion gene introduced into transgenic mice.
Expression of pharmaceutical directed to the mammary gland of transgenic
mice.
First transgenic bioreactor farm animals produced (sheep).
Mammary gland specific transgene expressed in goats.
Mammary gland specific transgene expressed in pigs.
Transgenic bull produced with mammary gland specific gene construct.
Bioreactor products being tested in animal models (preclinical testing).

(27)
(10)
(28)

1988
1991
1991
1991
1994

1Henryk

(69)
(22)
(79)
(43)
. . .1

Lubon (1994, personal communication).

and to reduce the microbial load in milk. One of the
most ambitious schemes that has been proposed is to
alter the composition of bovine milk so that it resembles human milk by eliminating some bovine milk
protein genes and replacing others with coding sequences derived from human genes. The resulting
milk, which would more closely resemble human
breast milk, would be used to supplement or replace
infant formula.
Economic Considerations
Genetic improvements in livestock will be judged
by the agricultural industry solely on total economic
merit. Assessing the cost-benefit ratios of a project is
a complicated process at best; assessing the economics
of projects directed toward solving problems of human
disease, which involve moral considerations, adds to
the complexity. However, the economics of even those
types of projects can and should be evaluated. Cost
assessment of the merits of a given strategy for improving livestock traits is more straightforward. With
current technology, the cost of producing transgenic
cows is so great that very few organizations have
been willing to invest in experiments designed to
assess the technical feasibility of altering cow’s milk
to create new food products. Without that information, it may be premature to speculate on other,
potentially larger, project costs that may be incurred
to alter marketing strategies and processing systems
and to meet regulatory requirements for the new
animal products.
Time is the greatest resource expended in a transgenic cattle project. Using techniques now considered
standard, 7 to 8 yr are needed to produce a milking
herd of transgenic dairy cattle. Policy makers should
not view this situation as a justification to abandon
the development of these technologies but, rather, as
an indication that additional research resources
should be made available to overcome the impediments that hinder progress.
Journal of Dairy Science Vol. 80, No. 9, 1997

Before gene modifications relating to the mammary
gland are discussed in detail, it is appropriate to
consider the current status of transgenic animal technology. This article addresses some of the hurdles
that continue to impede application of this technology
from solving agricultural problems.
TRANSGENIC ANIMAL MODEL SYSTEM
Most of the goals currently proposed for genetically
altering milk composition rely on gain of function
strategies (introduction of a new gene) by means of
pronuclear microinjection. However, eliminating or
reducing the concentration of specific proteins in milk
can also be achieved, at least in theory, by adding
new genetic information. By introducing ribozyme or
anti-sense genes, translation of specific milk protein
genes can be blocked or reduced, thus reducing their
protein concentration in milk.
A more widely accepted means of achieving loss of
function (eliminating or altering gene function) is
through use of gene “knock-out” technology that is
dependent on embryonic stems cell. Although outside
the scope of this review, development of embryonic
stem cells of domestic livestock is being pursued by a
number of groups, and embryo-derived pluripotent
cell lines have been reported for the pig ( 8 1 ) and cow
(71, 73); germline transmission from these cells has
not been reported. Recently, lambs were produced
following nuclear transfer from an established cell
line derived from sheep embryos (31). It remains to
be demonstrated whether these cells can be transfected with new genes and selected prior to nuclear
transfer and whether such cells can be isolated from
other livestock species.
Production of transgenic animals by pronuclear
microinjection is practiced today essentially as
described in the pioneering first report of Gordon et
al. (27), as further characterized by Brinster et al.
(11), and as adapted to livestock by our laboratory
(33, 78). Table 1 lists the milestones toward produc-
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tion of transgenic bioreactors. Interestingly, although
the technique has changed little, the definition of the
word “transgenic” has taken on new meanings. Jon
Gordon and Frank Ruddle originally proposed the
term to describe animals in which new genetic
material had been introduced by pronuclear microinjection (27). The term has been broadened considerably to include genetically engineered plants,
animals produced with the aid of stem cells, and
animals that have been subjected to in vivo somatic
cell engineering (injection of DNA directly into living
animals).
Efficiency of Producing
Transgenic Animals
The efficiency of producing transgenic animals is
low. A compilation of data from several laboratories
indicated that about 1 transgenic animal was
produced per 40 mouse eggs injected, and the efficiency for sheep, goats, and cattle was much lower,
requiring approximately 110, 90, and 1600 egg injections per transgenic animal, respectively (77). Furthermore, only about 50% of transgenic offspring express their transgene. To those working with mice,
low efficiency is not of particular concern, but low
efficiency is a major impediment to those attempting
to produce transgenic livestock. Three parameters account for the low efficiency of the process: embryo
survival, gene integration rate, and transgene behavior. In both livestock species and laboratory
animals, about 15% of microinjected, transferred embryos survive to term (77). However, gene integration frequency, as measured by proportion of animals
born that are transgenic, is much lower for livestock
species than for laboratory species (8, 33). That
difference in integration rate may be indicative of
important biological differences between the zygotes
of these species.
Transgene Integration Frequency
The genetic diversity of livestock species may affect
the low integration frequency observed. Laboratory
animals are derived from highly inbred lines, and
investigators often chose to use specific strains for
which embryos can be cultured easily. Scientists
working with livestock embryos do not have the same
inbred resources. However, there are obvious examples in the livestock industry of selection of animals
based on gamete quality. One example is the AI
industry in which selection of bulls is based not only
on genetic merit but also on the freezability of the
sperm. Very few researchers have the resources to
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perform the same kind of selection on embryo donors.
Another possible cause for the low rate of transgene integration may be related to procedural differences between microinjection of zygotes of livestock
and laboratory animals. Livestock eggs are more
challenging to microinject than are eggs of mouse,
rabbit, or rat. Cow and sow eggs must be centrifuged
before microinjection. Although little evidence exists
that embryo survival is compromised by centrifugation (78), the procedure may somehow influence integration rate. Within livestock species, the lower
integration rate that has been observed for cattle
embryos may be partially attributable to the increased difficulty of microinjecting cow eggs.
However, that difficulty is not likely to account for the
reduction in integration efficiency between cattle and
other livestock species.
It is also possible that transgenes become integrated at similar rates but that the development of
transgenic livestock embryos and fetuses is disproportionately compromised by transgenes. However, the
similar and poor survival rate of both laboratory and
livestock embryos does not support that hypothesis.
With the data available, it is not possible to determine to what extent susceptibility to transgenes or
expression of transgenes accounts for poor livestock
embryo survival. Those are probably not a major component (36).
A more compelling argument could be made for an
association of integration failure with the inappropriate timing of microinjection. It is well known that
transfection of cells in culture is most efficient in
dividing populations. Inference from that observation
is that DNA replication is required for integration of
foreign genes into the genome ( 4 ) , in which case, the
timing of pronuclear microinjection should be synchronized with onset of the DNA S-phase (synthesis
phase) of the first cell cycle to ensure the maximum
likelihood of an integration event. Mouse eggs are
microinjected at about 8 h postinsemination, resulting in DNA being introduced into zygotes during the
beginning of S-phase (44). Cow eggs are injected
toward the end of the S-phase (23, 24, 40), possibly
reducing the probability of an integration event.
Pronuclei in cattle zygotes form well before the normal timing of microinjection. However, the normal
timing of microinjection is restricted to the time that
pronuclei can be visualized in a nondestructive manner (differential interference contrast microscopy).
At earlier times, pronuclei cannot be found, even
though they are present. Therefore, it would seem to
be impossible to microinject transgenes before DNA
synthesis is nearly completed in cow eggs. ExJournal of Dairy Science Vol. 80, No. 9, 1997
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Figure 1. Time line (months) from microinjection to lactation of cows in a transgenic dairy herd arising from a male or female founder.
It is assumed that the gestation period is 9 mo, that both males and females reach sexual maturity at 15 mo of age, that the production
herd is sired ( A I ) by a single F1 male from a line known to express the transgene, and that the first calf of the female founder is male.

perimental evidence is lacking to support the influence of microinjection timing on the frequency of
transgene integration, and such evidence may be
difficult to achieve. Efforts to inject in vitro fertilized
bovine zygotes earlier than 13 h after insemination
have failed because of difficulties in visualizing
pronuclei and because attempts to manipulate the
timing of events during the first cell cycle have been
inconclusive.
Transgene Expression
Characteristics of transgene expression in transgenic goats, mice, pigs, rabbits, rats, and sheep appear to be similar. Although data are insufficient to
characterize transgene expression for transgenic cattle, there is no reason to expect that transgenes behave differently in that species. Transgenes appear to
integrate randomly in the genome, and approximately
half of transgenic animal lines express their transgenes, although some specific transgenes are expressed in a higher proportion of transgenic animals
(16, 29). Even in lines that express their transgene,
transgene expression is often inappropriate, occurring
in unintended tissues (ectopic expression) or at developmentally incorrect times. These aberrant expression patterns or lack of expression have been attributed to the “position effect”, which suggests that
neighboring genes or heterochromatin regions can
Journal of Dairy Science Vol. 80, No. 9, 1997

override the control of transgenes. Addition of matrix
attachment region sequences or genetic boundary elements to transgene constructs may overcome the position effect in lines that would otherwise carry nonfunctional transgenes (52).
Transgene Design
and Evaluation
The selection of appropriate regulatory regions,
coding sequence type (cDNA versus genomic), introns, and polyadenylation signals for design of mammary specific fusion genes has been severely hindered
by the lack of a rapid screening technique. Fusion
genes containing promoter regions that are specific to
the lactating mammary gland can only be evaluated
in lactating mammary epithelial cells. Unfortunately,
a transfectable, fully functional system for culturing
mammary cells has not been developed. Thus, the
labor-intensive and time-consuming transgenic mouse
model is viewed as the only reliable technique for
evaluation of gene constructs. Even with the relatively short gestation period of the mouse, meaningful
evaluation of a lactation-specific construct in F1
transgenic offspring requires a minimum of 6 to 12
mo. As an initial screening tool, we are developing an
in situ transfection technique based on jet injection of
naked DNA into lactating mammary glands (25). At
2 d after jet injection of plasmid DNA containing the
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human growth hormone ( hGH) gene, driven by the
human cytomegalovirus promoter-enhancer region
into mammary glands of lactating sheep, transgene
expression was sufficient to be detected by Northern
blot analysis (41). We are now using this technique
to compare the potencies of various mammary-specific
promoter regions in directing expression of the hGH
gene (42). Expression is being assessed by both
Northern blot analysis and by measurement of hGH
protein in tissue extracts. Using the ovine b-LG
promoter, up to 40 ng/ml of hGH protein has been
detected in the extracts of mammary tissue obtained
48 h postinjection. We are confident that this approach will speed the process of transgene evaluation,
serving as a preliminary screening technique prior to
the transgenic mouse model, which is much more
labor intensive. Finally, because the gene product
(protein) can be detected after jet injection of the
gene construct, evaluation of posttranslational capabilities of the target tissue in the target species is
possible.
Time Requirements
for Transgenic Animal Projects
Time is by far the greatest resource expended in
transgenic livestock projects, as is clearly shown in
projects in which the transgene is designed to express
only in the lactating mammary gland. In such
projects, the minimum time from microinjection to
evaluation of milk is equal to twice the gestation
length of the target species plus the time from birth to
puberty. Once a useful line has been identified, the
next step is to collect semen in order to generate a
production herd. The time required to achieve these
milestones using standard techniques is presented in
Figure 1. Clearly, there is a need to develop strategies
that shorten the 7 yr to production.
A number of strategies have been demonstrated or

proposed to reduce the time that is required to identify and evaluate transgenic dairy animals as well as
the time that is required to expand successful lines
( 7 ) . For example, expression of a lactation-specific
transgene has been detected in milk obtained by artificial induction of lactation in female and male goats
(21). More recently, expression of a fusion gene composed of the bovine aS1-CN promoter driving the hGH
gene was detected by mammary biopsies obtained 24
h after birth of both male and female rats (37). If
such a strategy were proved to reflect transgene expression in adults, then semen from a transgenic bull,
collected at approximately 15 mo of age ( 2 yr following microinjection), could be used to generate a herd
producing genetically modified milk in approximately
3 yr—about 5 yr from the time of microinjection.
TRANSGENIC ANIMAL BIOREACTORS
A number of companies have been formed within
the last decade specifically to exploit transgenic technology. This new industry has been created based on
the assumption that production of pharmaceuticals in
transgenic animals is more cost effective than production by more conventional means. The US market for
bioreactor products thus far identified exceeds $3
billion/yr (Table 2). All of the products listed in Table
2 are currently derived from human blood, which may
account for the fact that the American Red Cross
Blood Derivatives Laboratory is one of the leaders in
the bioreactor field.
Advantages of Transgenic
Animal Bioreactors
Almost any living organism, or part thereof, that
can be cultivated can serve as a bioreactor. Bacteria,
yeast, insect cells, mammalian cells in culture, plants,
and chicken eggs are all potential competing produc-

TABLE 2. Estimated annual US requirements and costs of some potential bioreactor products.1
Pharmaceutical
VIII2

Item

F

Estimated quantity needed, kg
Current cost per gram, $
Annual market, $ × 106

0.3
2,900,000
882

F

IX3

4
40,000
160

Protein C

AT III4

Fibrinogen

Albumin5

10
10,000
100

21
7000
150

150
1000
150

315 × 103
3.56
1120

1Information

from William Drohan and Henryk Lubon, American Red Cross (46, 56).
coagulating factor VIII.
3Blood coagulating factor IX.
4Antithrombin III.
5Human serum albumin.
2Blood

Journal of Dairy Science Vol. 80, No. 9, 1997
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tion systems. Each system has specific advantages
and disadvantages. In general, prokaryotic systems
and plants can be genetically engineered and
propagated rapidly at relatively low cost but lack the
mechanisms, or possess the wrong machinery, to perform some of the critical posttranslational modifications (e.g., signal peptide cleavage, glycosylation,
amidation, acetylation, carboxylation, and phosphorylation) that are required by complex mammalian proteins (38). Systems for baculovirus-insect cell expression ( 4 7 ) and stable transfected mammalian cells
have the capacity to perform authentic posttranslational modifications, but yields in those systems are
often an order of magnitude lower than those already
achieved in transgenic animal bioreactors.
Advantages of the Transgenic
Mammary Gland
The mammary gland is a prodigious production
system that is capable of generating between 23 g
(dairy cattle) and 205 g (rat) of protein/kg of body
weight during peak lactation (55). Milk is clearly the
easiest body fluid to collect, especially from
ruminants; even pigs can be milked mechanically
(30). The ample production capacity of the mammary
gland, coupled with the relative ease of harvesting
milk in a noninvasive manner, recommends the mammary gland as the organ of choice for producing pharmaceutical products from animals.
Another often cited advantage of producing biologically active products using the mammary gland is the
isolation of the mammary gland from the circulatory
system. It is argued that bioreactor animals would be
protected from the potentially untoward effects of
biologically active compounds because those compounds would be sequestered in the mammary gland
and therefore would be unavailable to the circulatory
system. However, endogenous milk proteins are indeed found in the circulation in cattle, especially during late gestation and at parturition (51), and transgenes and milk protein genes are transiently
expressed during estrus, even in virgin mice (64).
Therefore, to safeguard bioreactor animals, it may be
appropriate to consider designing gene constructs in
such a way that their product is converted to an
active form after it is isolated from milk.
A potential hurdle to the success of mammary
gland bioreactors lies in the ability of the alveolar
epithelium to provide appropriate posttranslational
modifications such as cleavage of propeptides or signal peptides, N- or O-glycosylation, and g-carboxylation. Lack of faithful posttranslational modification
Journal of Dairy Science Vol. 80, No. 9, 1997

of a protein is assumed to affect its biological activity.
Furthermore, carbohydrate residues of glycoproteins
can serve as antigens, can also influence secretion of a
protein, and can affect the half-life of a protein in the
circulation (39).
It has recently been shown that, when transgenes
for interferon-g were expressed in ovary cells of
Chinese hamsters, Sf9 insect cells infected with
baculovirus, and mammary glands of transgenic mice,
N-glycosylation patterns (sites glycosylated) and
composition of the sugar residues differed significantly (39). Glycosylation patterns of human Protein
C produced in the mammary glands of transgenic
mice ( 2 0 ) or transgenic pigs ( 5 4 ) have been demonstrated to differ from each other and from Protein C
isolated from human serum. No additional data are
available to assess the significance of these observations on the biological activity of this protein or on the
production of other pharmaceuticals in milk.
However, at least one prominent laboratory in the
bioreactor field is beginning to address the issue by
creating transgenic mice that contain two transgenes
directed toward the mammary gland, one for the protein of interest and the other to increase the posttranslational modification capabilities of the gland
(19).
Production Capacity
of Transgenic Mammary Glands
Transgene production capacity is difficult to predict
with any certainty. However, from the growing list of
studies on transgenic animals in which a milk protein
promoter has been used to direct expression of pharmaceutical (Table 3 ) or milk protein (Table 4 ) into
milk, reasonable production would be at least 1 mg/
ml.
The bovine is the target species for transgenic
projects aimed at modifying milk for the dairy industry. For bioreactor projects, the target species will be
determined on product demand. At an assumed
production level of 1 mg/ml, one can calculate the
number of animals that would be required to produce
some of the proposed pharmaceutical bioreactor
products. The results of those calculations are
presented in Table 5. On first inspection, it seems
unreasonable to think that an organization would
consider generating the more than 27,000 rabbits
necessary to produce 150 kg of fibrinogen. The labor
that is required to maintain and milk those animals
would be enormous, especially in light of the fact that
17 cows might be capable of producing all of the
fibrinogen required to satisfy current world needs.
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TABLE 3. Summary of transgenic animal studies in which a milk protein promoter was used to direct
expression of a milk protein into milk.
Coding sequence

Promoter region

Transgenic
species

Gene

Source

Gene

Source

Protein in
milk1

Murine

a-LA

Bovine

a-LA

Bovine

(mg/ml)

Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Porcine
Ovine
Bovine

a-LA
a-LA
b-LG
aS1-CN
b-CN
b-CN
a-CN
b-CN
k-CN
k-CN
Lactoferrin
Lysozyme
WAP3
WAP
WAP
WAP
Lactoferrin

Caprine
Guinea pig
Ovine
Bovine
Bovine
Bovine
Caprine
Rat
Bovine
Caprine
Human
Human
Murine
Rat
Murine
Murine
Human

a-LA
a-LA
b-LG
aS1-CN
b-CN
a-LA
b-CN
b-CN
b-CN
b-CN
as1-CN
as1-CN
WAP
WAP
WAP
WAP
as1-CN

Caprine
Guinea pig
Ovine
Bovine
Bovine
Bovine
Caprine
Rat
Caprine
Caprine
Bovine
Bovine
Murine
Rat
Mouse
Mouse
Bovine

mg
ND2
mg
ND
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
ND

Reference
(5,
(76)
(70)
(50)
(35,
(15)
(62)
(6)
(58,
(45)
(31)
(57)
(59)
(48)
(13,
(2,
(66,
(80)
(43)

70)

68)

63)

52)
16)
79)

1Precision of protein determinations varied between publications. Therefore, only the order of
magnitude of concentration is given for comparison purposes.
2Not determined.
3Whey acidic protein.

TABLE 4. Summary of transgenic animal studies in which a milk protein promoter was used to direct
expression of a pharmaceutical protein into milk.
Transgenic
species
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Murine
Rabbit
Rabbit
Porcine
Ovine
Ovine
Caprine

Coding sequence
Gene
a1-Antitrypsin
a1-Antitrypsin
b-Interferon
g-Interferon
CFTR4
Factor IX
Protein C
Serum albumin
Superoxide
dismutase
Superoxide
dismutase
t-PA5
t-PA
Trophoblastin
Urokinase
Interleukin-2
t-PA
Protein C
a1-Antitrypsin
Factor IX
t-PA

Promoter region

Source

Gene

Source

Protein
in milk1

Reference

Murine
Human
Human
Human
Human
Human
Human
Human

WAP2
b-LG
WAP
b-LG
b-CN
b-LG
WAP
b-LG

Rabbit
Ovine
Murine
Ovine
Caprine
Ovine
Murine
Ovine

(mg/ml)
mg
ND3
ng
mg
mg
ng
mg

(3)
(1)
(65)
(18)
(17)
(85)
(75)
(67)

Human

b-LG

Ovine

ng

(34)

Human
Human
Human
Ovine
Human
Human
Human
Human
Human
Human
Human

WAP
WAP
as1-CN
a-LA
as1-CN
b-CN
as1-CN
WAP
b-LG
b-LG
WAP

Murine
Murine
Bovine
Bovine
Bovine
Rabbit
Bovine
Murine
Ovine
Ovine
Murine

mg
ng
mg
mg
mg
ng
mg
mg
mg
ND
mg

(34)
(28)
(61)
(72)
(53)
(12)
(61)
(74)
(83)
(69)
(22)

1Precision of protein determinations varied between publications. Therefore, only the order of
magnitude of concentration is given for comparison purposes.
2Whey acid protein.
3Not determined.
4Cystic fibrosis transmembrane receptor.
5Tissue plasminogen activator.
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However, the required number of rabbits could be
produced in 3 to 4 yr by using homozygous males and
AI, but 7 to 8 yr would be needed to produce the 17
cows. This comparison is exaggerated but points out
the need to consider generation interval as well as
production capacity when choosing a species for a
bioreactor project.
The data presented in Table 5, admittedly based on
preliminary findings, bode well for the practical ability for genetic engineering of mammary glands to
produce commercially useful concentrations of foreign
protein. Nevertheless, the amount of transgene proteins produced are lower than those of endogenous
proteins for all species with the possible exception of
sheep. Are the relatively modest concentrations of
transgene proteins that have been observed the result
of inept transgene design, or are mammary glands
already producing close to their maximum capacity?
Will milk protein genes have to be knocked out to
provide additional capacity for transgene proteins?
Will higher transgene product production levels be
disruptive to mammary gland function as they were
in one study ( 6 ) ? These questions cannot be answered at this time.
MODIFICATION OF MILK TO IMPROVE
NUTRITION AND PROCESSING
As mentioned at the outset, a variety of ways have
been suggested to modify milk to improve its nutritional quality and to improve the efficiency of
manufacturing milk products such as cheese, ice
cream, and yogurt (Table 6). Unfortunately, this
area of investigation has received less attention in
laboratories than it has in review articles.
The limited efforts in this area of research, compared with research in pharmaceutical production,

may reflect the perceived rate of financial return on
food products compared with the return on biomedical
products. However, a less obvious factor may also
have influenced the differences in emphasis of the two
fields of genetic engineering. A significant segment of
the pharmaceutical industry has embraced the transgenic bioreactor as an approach to making drugs, but
little evidence exists that the dairy industry has been
as enthusiastic about modifying the type of milk that
cows produce. The pharmaceutical industry has a
history of obtaining its products from a variety of
sources—extracting drugs from plants, synthesizing
drugs from chemical constituents, and isolating drugs
from animal and human tissues. Isolating these
products from the milk of genetically engineered
animals does not require a significant change in mind
set. However, the prospect of creating cows that
produce specialized milk may have momentous consequences for the structure of the dairy industry.
The goal of the dairy industry, at least in the US,
has been to create an efficient, healthy cow producing
copious amounts of milk that can serve all the needs
of the industry. Genetic engineering offers the opportunity for a paradigm shift, a reshaping of the industry from the producers to the processing plants. Dairy
producers have the opportunity to choose to produce
high protein milk; milk destined for cheese manufacturing that has accelerated curd clotting time; milk
containing nutraceuticals, orally administered biologics that provide a health benefit; or a replacement for
infant formula. Such a scenario would be a radical
change for the dairy industry. But this scenario is by
no means without precedent in agricultural production systems. One only has to look to grain, fruit, and
vegetable crops to see numerous examples of varieties
that have been propagated to fill or create specific
niche markets. Whether such a paradigm shift will

TABLE 5. Estimated number of transgenic animals needed to satisfy the annual US market for
selected pharmaceuticals.1
Pharmaceutical
Species

F

Rabbit
Porcine
Ovine
Caprine
Bovine

54
1
1
1
1

VIII2

1Based

F

IX3

714
10
13
7
1

Protein C

AT III4

Fibrinogen

Albumin5

1785
25
33
17
2

3750
53
70
35
3

27 × 103
380
500
250
17

56
800
1050
525
35

×
×
×
×
×

106
103
103
103
103

on estimated quantity needed (Table 2 ) and a transgene protein production of 1 g/L.
coagulating factor VIII.
3Blood coagulating factor IX.
4Antithrombin III.
5Human serum albumin.
2Blood
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TABLE 6. Some proposed modifications of milk constituents.1
Change

Consequence

Increase a- and b-CN

Enhanced curd firmness for cheese making, improved thermal stability, and increased calcium
content.
Increased calcium content and improved emulsification.
Increased rate of textural development (improved cheese ripening).
Enhanced stability of casein aggregates,
decreased micelle size, and decreased gelation
and coagulation.
Decreased high temperature gelation, improved
digestibility, decreased allergenic response, and
decreased primary source of cysteine in milk.
Decreased lactose, increased market potential of
fluid milk, decreased ice crystal formation, and
compromised osmotic regulation of mammary
gland.
Enhanced iron absorption and protected against
gut infections.
Increased rate of cheese ripening.
Decreased fat content, improved nutritional
quality, and reduced milk production costs.
Protected against pathogens such as salmonella
and listeria.
Mimicked human breast milk.

Increase phosphorylation sites in caseins
Introduce proteolytic sites in caseins
Increase k-CN concentration
Eliminate b-LG
Decrease a-LA

Add human lactoferrin
Add proteolytic sites to k-CN
Decrease expression of acetyl-CoA carboxylase
Express Ig genes
Replace bovine milk proteins genes with
human equivalents
1Adapted

(14, 38, 84).

sweep through the entire dairy industry or become a
subset of the industry remains to be seen. There is,
however, little question that products of genetic engineering will become part of the dairy industry in
the next century.
Many of the proposed changes in milk structure are
listed in Table 6. It is readily apparent that a number
of ways may be used to achieve the same or similar
goals. Clearly, altering the characteristics of one component to enhance a particular processing feature
may make milk unsuitable for other uses. During the
next decade, dairy scientists must determine which
approach is most efficacious to achieve the desired
goal.
Gibson ( 2 6 ) recently published a thorough analysis of the economic potential of altering milk fat composition and pointed out several potential limitations
to that strategy. One consequence of altering milk fat
composition would be that increasing the proportion
of unsaturated fats (and as a consequence decreasing
saturated fats) would increase the melting point of
milk, which could impair whipping of cream and increase the hardness of butter. Furthermore, if the
alterations resulted in increased free fatty acids, milk
rancidity would likely increase. Gibson ( 2 6 ) concluded that the interactive consequences of altering
fat content of milk on processing of other milk

products would not be economically advantageous to
large segments of the dairy industry, but would only
be suitable for niche markets.
However, if the goal is to decrease total fat content
rather than to alter the ratios of various fat components, a different economic picture emerges. On average, dairy cows in the US produce milk that contains
3.8% fat. Approximately 50% of that fat is synthesized in the mammary gland. Therefore, if that synthetic machinery in the mammary gland could be
disrupted, milk containing 2.0% fat ( a 40% reduction) might be achievable (84).
Bremel et al. ( 9 ) have suggested that de novo fat
synthesis might be reduced by blocking expression of
the acetyl-coenzyme A ( CoA) carboxylase gene
through stem cell (“knockout”), antisense, or ribozyme technology. A recent study ( 3 2 ) confirmed the
potential of this concept by transfecting preadipocyte
cells with a ribozyme gene directed against acetylCoA carboxylase RNA. Acetyl-CoA carboxylase RNA
was reduced compared with nonribozyme-expressing
cells. The decrease in acetyl-CoA carboxylase mRNA
was associated with a significant decrease in activity
of acetyl-CoA carboxylase enzyme, and the rate of
fatty acid synthesis fell to about 30 to 70% that of
controls. This strategy would also have collateral consequences, but might be very cost effective.
Journal of Dairy Science Vol. 80, No. 9, 1997
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Fats are energetically expensive molecules to
make, and reducing the fat content of milk to 2.0%
could reduce feed energy requirements. Typical dairy
rations consist of about 60% forage and 40% concentrate. The cost of forage accounts for about 40% of the
cost of feed, and the grain component accounts for
about 50% of the feed cost. Engineering of cows to
produce 2.0% fat milk would allow the forage component of rations to be increased to 83% (84). The
consequence of that change in feed composition would
be a reduction of 22% in feed cost per kilogram of
milk. Notwithstanding significant savings to the
dairy producer, further ramifications could have a
positive environmental impact. The amount of forage
production would have to be increased by 33%, but
the amount of corn produced for dairy rations could be
decreased by 50%. Based on corn and forage yields at
Beltsville, an acre of land could be taken out of corn
production for every 4 cows engineered to produce
2.0% fat milk. Over 2 million acres used for grain
production could be reclaimed if all 10 million dairy
cows in the US were genetically engineered to
produce 2% fat milk. Admittedly, this occurrence is
unlikely but demonstrates the potential impact that
genetic engineering of dairy cattle could have on other
aspects of agriculture.
CONCLUSIONS
The most easily identified constraint impeding
progress in this field is the difficulty in producing
useful transgenic animals. As mentioned earlier, low
rates of embryo survival and transgene integration
have clearly been documented. Because of those two
factors, producing a transgenic sheep or goat can
easily cost $60,000, and producing a transgenic cow or
bull can exceed $300,000. The situation is further
exacerbated by the unpredictable behavior of fusion
gene constructs. Currently, no foolproof method to
assess the function of a transgene exists, other than
to use it to make transgenic animals of the species of
interest. Most organizations test transgene constructs
in mice before introducing them into livestock.
However, transgenic mice have proved to be poor
predictors of transgene function in another species. A
way must be found to evaluate transgene constructs
accurately in the tissue of the animal of choice
without requiring the investment of time and money
to produce transgenic livestock. Increased efficiency of
producing transgenic animals not only would have
the obvious benefit of reducing costs, but also would
encourage participation in this field by investigators
who cannot currently afford to use this technology.
Journal of Dairy Science Vol. 80, No. 9, 1997

The participation of other researchers is necessary,
especially in the area of modifying milk for postharvesting processing purposes because of the great deal
of expertise and research that is required to link the
fields of transgenic animal production and dairy food
science.
Transgenic animal bioreactor organizations have
demonstrated, mostly through empirical studies, that
almost any desired protein can be produced in mammary glands. This field of research has now reached
the stage of maturity at which the focus of attention
will shift to concerns of posttranslational modifications of those proteins, efficacious purification
schemes, and product safety. Sixteen years ago, transgenic animal technology was invented, and, since
then, an industry has formed to exploit that technology. In the next 16 yr, products created by that technology will likely be in the hands of consumers.
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